Charles Schwab
RPRX

Charles Schwab’s Repros Therapeutics Inc. RPRX Stock Holding History

Charles Schwab’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-32,700
Closed -$281K – 3232
2015
Q1 		$281K Hold
32,700
– – ﹤0.01% 2862
2014
Q4 		$327K Hold
32,700
– – ﹤0.01% 2807
2014
Q3 		$324K Hold
32,700
– – ﹤0.01% 2766
2014
Q2 		$566K Hold
32,700
– – ﹤0.01% 2573
2014
Q1 		$581K Hold
32,700
– – ﹤0.01% 2534
2013
Q4 		$599K Hold
32,700
– – ﹤0.01% 2519
2013
Q3 		$886K Buy
32,700
+6,000
+22% +$129K ﹤0.01% 2269
2013
Q2 		$511K Buy
+26,700
New +$472K ﹤0.01% 2520

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Charles Schwab's RPRX Position: Q2 2015 in Review

Charles Schwab sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 32,700 shares — an estimated $281K sold.

Charles Schwab first reported a position in RPRX in Q2 2013 and held it in 8 quarters. The position peaked at $886K in Q3 2013. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

  • Charles Schwab reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
  • Charles Schwab sold 32,700 Repros Therapeutics Inc. shares in Q2 2015, an estimated $281K.
  • Charles Schwab first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 8 quarters.
  • Charles Schwab's Repros Therapeutics Inc. position peaked at $886K in Q3 2013.
  • 64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on Charles Schwab's 13F filing for Q2 2015, filed 14 Aug 2015.